Individualizing Insulin for Patients Who Fear Hypoglycemia: Using Evolving Basal Insulins to Minimize Adverse Effects
Vivian Fonseca, MD
Professor of Medicine and Pharmacology
Assistant Dean for Clinical Research
Tullis Tulane Alumni Chair in Diabetes
Chief, Section of Endocrinology
Tulane University Health Sciences Center
New Orleans, LA
Timothy S. Reid, MD
Mercy Diabetes Center
Jaime Symowicz, PhD
Manager, Educational Strategy and Content
Kathryn Schaefer, MSN, RN, CPHRM
Senior Manager, Accreditation and Compliance
East Lansing, MI
Upon completion, participants should be able to:
- Outline insulin-based treatment strategies that maximize glycemic control while limiting adverse effects among patients with a history of severe hypoglycemia
This activity is intended for family practice physicians, general practice physicians, internal medicine physicians, primary care physicians, nurse practitioners, physician assistants, and nurses.
Statement of Need
Data reported in the 2017 National Committee for Quality Assurance State of Health Care Quality Report show that between 23.3% (Medicare) and 43.3% (Medicaid) of patients with diabetes have HbA1C levels above 9%. Although insulin therapy has been demonstrated to improve glycemic control in individuals with type 2 diabetes, its initiation and intensification are frequently delayed as a result of both clinician- and patient-related barriers. To overcome these challenges, clinicians need to first identify their patient’s concerns about starting or advancing insulin. This information can help them select appropriate regimens to encourage treatment adherence and realize glycemic goals. A basal insulin analog is often the first insulin formulation recommended because of its convenient initial dosing schedule and low risk of hypoglycemia, but clinicians should also be aware of new formulations of long-acting basal insulins when individualizing their patient’s insulin regimens.
Provided by Med-IQ.
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Med-IQ designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Med-IQ is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
This nursing activity has been approved for up to 0.25 contact hour.
Physician assistants and other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available.
Instructions to Receive Credit
To receive credit, read the introductory CME/CE material, watch the webcast, and complete the evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.
Initial Release Date: December 6, 2018
Expiration Date: December 5, 2019
Estimated Time to Complete This Activity: 15 minutes
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.
Vivian Fonseca, MD
Consulting fees/advisory boards: Bayer HealthCare Pharmaceuticals, Boehringer-Ingelheim Pharmaceuticals, Inc.
Contracted research: Asahi Kasei Pharma Corporation, AstraZeneca, Eli Lilly and Company, Intarcia Therapeutics, Inc., Novo Nordisk, Sanofi Genzyme, Takeda Pharmaceuticals North America, Inc.
Timothy S. Reid, MD
Consulting fees/advisory boards: AstraZeneca, Intarcia Therapeutics, Inc., Janssen Pharmaceuticals, Inc., Novo Nordisk, Sanofi Genzyme
Fees received for promotional/non-CME activities: Janssen Pharmaceuticals, Inc., Novo Nordisk, Sanofi Genzyme
The peer reviewers and activity planners have no financial relationships to disclose.
Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, it is the policy of Med-IQ to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.
Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.
For questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or email firstname.lastname@example.org.
Operating system - Med-IQ supports the following operating systems:
- Microsoft Windows supported by Microsoft
- Mac OS supported by Apple
Browsers - Med-IQ supports the current version of each browser listed below, plus two prior versions:
Microsoft Internet Explorer
- Microsoft Edge
Operating system - Med-IQ supports the current operating system, plus two prior releases:
- Android (eg, Samsung Galaxy)
- Apple (eg, iPhone/iPad)
Browsers - Med-IQ supports the default browser for the applicable operating system release, plus two prior releases:
- Android (Chrome)
- Apple (Safari)
Applications & Software
PDF Viewer - Adobe Acrobat Reader or Adobe Reader
Adobe Flash Player - Med-IQ supports the current version, plus two prior versions
For technical assistance, please refer to our Support Manual.
Med-IQ fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please contact Med-IQ at 443 543 5200.
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Privacy & Confidentiality
Acknowledgment of Commercial Support
This activity is supported by an educational grant from Sanofi US.
© 2018 Med-IQ, Inc.
The following material has been developed to accompany this activity:
Note: This material is not accredited for CME and, therefore, does not offer any CME/CE credit.
Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.